Stopping Tirzepatide Before Surgery and Anesthesia

If you take tirzepatide (Zepbound or Mounjaro) and have a procedure coming up that involves anesthesia or sedation — surgery, a colonoscopy, an endoscopy, even some dental work under sedation — there is one question your anesthesia team will care about more than any other: is your stomach actually empty? Tirzepatide slows how fast the stomach empties, and that is the whole reason this drug intersects with surgical safety. This guide explains the real risk, what the FDA label and anesthesia guidance actually say, and how the timing decision is made — without overstating a danger that is, for most people, manageable with a plan.

The honest framing up front: this is a precaution about one specific risk — pulmonary aspiration — not a sign that tirzepatide is unsafe. The decision to pause it, and for how long, is individualized and belongs to your surgeon and anesthesiologist, not to a generic internet rule. What follows is what the evidence and the guidance say so you can have an informed conversation with them.

Why slowed gastric emptying is the issue

Tirzepatide is a dual GIP and GLP-1 receptor agonist, and like the GLP-1 class it delays gastric emptying — food and liquid leave the stomach more slowly than normal¹. That delayed emptying is part of how the drug curbs appetite, and it is also why the FDA prescribing information explicitly lists, among its warnings, the potential for retained gastric contents and a risk of pulmonary aspiration during general anesthesia or deep sedation¹.

Pulmonary aspiration means stomach contents come back up and are inhaled into the lungs while the airway's protective reflexes are suppressed by anesthesia. The standard pre-procedure fasting rules exist precisely to keep the stomach empty so this can't happen. The concern with GLP-1-class drugs is that even after a normal overnight fast, the stomach may not be as empty as the fasting time would normally guarantee.

That concern is not purely theoretical. Endoscopy studies — where a camera directly visualizes the stomach — have found that patients on GLP-1 receptor agonists are more likely to have retained solid food in the stomach despite following standard fasting instructions. A retrospective endoscopy analysis found semaglutide use was associated with retained gastric contents on the day of the procedure², and a propensity-matched study of patients undergoing colonoscopy found a measurable increase in markers of aspiration risk among GLP-1 users³. A review focused on the perioperative period concluded that the delayed gastric emptying these drugs cause is a real consideration for anesthesia planning⁴. The signal is consistent enough that anesthesia bodies changed their guidance over it.

What the guidance actually says — and where it has moved

In 2023, the American Society of Anesthesiologists (ASA) issued guidance recommending that GLP-1 receptor agonists be held before elective procedures requiring anesthesia or deep sedation — holding daily-dosed agents on the day of the procedure and weekly-dosed agents (like tirzepatide) for roughly a week beforehand — to reduce aspiration risk. That conservative "hold it" position is the source of the widely repeated "stop about a week before" rule for weekly injectables.

The picture has since become more nuanced. Newer multi-society and consensus guidance has moved toward an individualized, risk-based approach rather than a blanket hold for everyone — weighing the urgency of the procedure, the dose and how recently it was taken, GI symptoms, and whether the stomach can be assessed (for example, with point-of-care ultrasound) on the day. A comparison of how different clinical practice guidelines handle non-insulin glucose-lowering drugs before surgery shows exactly this divergence, with recommendations ranging from holding the drug to mitigating risk through a clear-liquid diet and gastric assessment instead⁵. In short: the field agrees the risk is real, but no longer universally agrees that everyone must stop a full week out.

This is why a generic number is the wrong thing to anchor on. Depending on the procedure and the guidance your hospital follows, you may be told to hold tirzepatide for the week before (since it is weekly-dosed, that often means simply skipping the dose that would fall in the pre-op week), or you may be managed with an extended clear-liquid diet and a day-of stomach assessment instead. Some surgical teams ask for as long as 10 to 14 days; others individualize. The only correct source for your number is your own surgical and anesthesia team.

What this means for the perioperative-risk evidence

It is worth being precise about what the risk evidence does and does not show. The documented signal is for retained gastric contents and aspiration risk markers, not a high rate of catastrophic aspiration events in well-managed patients. A nationwide propensity-matched study of preoperative GLP-1 use looked at perioperative cardiorespiratory complications and mortality and provides population-level context on the size of the risk⁶ — useful for keeping the concern proportionate. The mainstream interpretation is that this is a manageable, mitigatable risk, which is exactly why the response is a timing-and-fasting plan rather than a recommendation to avoid the drug.

None of this changes the established facts about why people take tirzepatide in the first place. The SURMOUNT-1 obesity trial showed mean weight reductions reaching roughly 21% at the 15 mg dose over 72 weeks⁷, and a systematic review across the trial program characterized its GI effects — including the delayed emptying behind this whole discussion — as generally mild to moderate and dose-dependent⁸. The surgical pause is a short, specific safety measure layered on top of an effective long-term therapy, not a reason to abandon it.

Practical planning checklist

When you know a procedure is coming, do these things:

• •Tell every member of your care team that you take tirzepatide — the surgeon, the anesthesiologist, and the pre-op nurse. Do not assume it's in your chart or that they'll ask. This single disclosure is the most important step.
• •Ask for your specific hold instruction in advance, including whether they want you on an extended clear-liquid diet before the procedure.
• •Do not stop on your own and then restart erratically. Because tirzepatide is weekly and is titrated up a fixed ladder, gaps and restarts have their own rules; see our guide to what happens if you stop tirzepatide for why an unplanned gap can mean re-titrating.
• •Follow fasting instructions exactly — and tell the team honestly if you ate or drank anything, because that changes the airway plan.
• •Plan the restart with your prescriber, not by guesswork, especially after abdominal surgery where eating is changing anyway.

For the mechanics of resuming injections — sites, rotation, and storage — see how and where to inject Zepbound, and for where each dose sits on the titration ladder if a gap forces a restart, see the tirzepatide dosage chart.

The honest bottom line

Tirzepatide slows gastric emptying, which can leave food in the stomach longer than a normal fast would suggest — and that creates a real, FDA-labeled risk of pulmonary aspiration under anesthesia¹. That risk, confirmed in endoscopy and perioperative studies²³, is the reason anesthesia guidance recommends managing the drug before procedures. The original 2023 ASA position was a conservative "hold weekly agents about a week beforehand," but guidance has since moved toward individualized, risk-based management⁵ — which is exactly why the right answer to "how long before surgery do I stop?" is a conversation with your surgical and anesthesia team, not a fixed number from an article. The risk is real, specific, and manageable with a plan. For the full evidence picture on the drug itself, see our tirzepatide evidence guide, and to compare your options for obtaining it, start with best tirzepatide.